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<s>Oral Surgery 
<t>IDBs Versus Infiltration Dentistry: Is it time for change? 
<a>Tara Renton, BDS MDSc PhD, Professor Oral Surgery, Kings’ College London, 
Bessemer Road, Denmark Hill London SE5 9RS, UK. 
<a/c>Abstract: Dentistry is unique in that high volume surgery is undertaken 
efficiently on conscious patients, an anathema to most other surgical specialties who 
predominantly operate on unconscious patients. Local anaesthesia provides an efficient 
block to nociceptive pain (the first stage of the pain pathway) but only addresses one 
small part of the pain experience. Currently the inferior dental block (IDB) is the ‘go 
to’ standard for dental LA for mandibular dentistry despite its significant 
shortcomings. Unfortunately, as creatures of habit we continue to practise what is 
taught to us at dental school, IDBs, when evolving more patient safe practice takes 
considerable time to be taken up by the workforce. 
Local anaesthesia blocks are inefficient in providing swift pulpal anaesthesia. Malamed 
stated that the rate of inadequate anaesthesia ranged from 31% to 81%. When 
expressed as success rates, this indicates a range of 19% to 69%. These numbers are 
so wide ranging as to make selection of a standard for rate of success for IANB 
seemingly impossible. LA blocks also increase the risk of systemic complications and 
they are associated with nerve injury. Though LA-related permanent nerve injury is 
rare (approximately 1in 52−7K IDBs), once the injury occurs approximately 75% may 
resolve but the remaining 25% are untreatable. Most patients with trigeminal nerve 
injuries experience chronic pain in their lip, teeth and gums or tongue and gums, 
depending on which nerve is damaged. This is a lifelong burden that these patients find 
difficult to accommodate, especially when they were never warned about the possible 
risk. 
The risk of nerve injury can be mitigated by altering the block technique or by avoiding 
block anaesthesia altogether. With novel development in pharmacology of LA and 
equipment, block anaesthesia is likely to become rarely needed in dentistry. 
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<a/c>CPD/Clinical Relevance: Dentistry is a profession predicated upon causing and or 
managing pain in patients. Providing effective pain control during surgery is essential 
but using techniques with the minimum risks is imperative. 
<ch1/1>So how can we improve our local anaesthetic practice? 
There are four questions that we should first address in critiquing existing LA practice 
and assess if there is need for improvement. 
1. What is the role of LA in managing analgesia for dental patients? 
-An update on pain 
-The patients’ perspective 
2. How do we minimize systemic complications of dental LA? 
-Systemic issues for LA 
3. What are the medical modifiers for dental LA? 
4. How do we minimize regional complications of LA? 
-Avoiding failed LA 
-Avoiding local complications including LA nerve injuries 
How can we do better? Proposed tailored smart LA practice: 
• What technique? 
• What Agent? 
• What LA volume? 
<ch1/1>What is the role of LA in managing analgesia for dental patients? 
Patients want two main outcomes when they visit a dental practice, first pain free 
injections and second painless procedures.1 However, needles and tablets are but a 
small part of the holistic pain management of dental patients.2 The definition of pain is 
that it is ‘an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage’.3 The brain overlays the 
pain sensation on the part of the body that’s getting hurt to protect it from harm. 
There are four types of pain:4 two healthy and two pathological. Healthy protective 
pain includes firstly; nociceptive pain, which is the conversion of tissue injury and 
release of algogenic factors (intracellular components released due to cell damage) 
which act as ‘foreign bodies’ exciting pain receptors on nociceptive nerve fibres (C, A 
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delta and A beta fibres). These cause transduction from chemical inflammation into an 
action potential and the progression of an action potential advancing up to the tertiary 
order neurones to the somatosensory cortex; once reached the ‘ouch’ is acknowledged 
resulting in reflex withdrawal of the digit from danger. Inflammatory pain follows 
nociceptive pain, if tissue damage occurs promoting tissue healing. This process should 
usually resolve in days or weeks, depending on the degree of damage and persistence of 
infection. 
Local anaesthesia blocks nociceptive pain very successfully but, due to pain multiple 
components there is increasing evidence supporting the education of patients in 
expected pain levels (managing their expectations), being caring, empathetic, providing 
appropriate anxiolysis, distraction and, on occasions, providing this alone is not enough 
to manage perioperative pain in patients. Some patients may be stoic types (‘rugby 
player’) able to cope with the anticipated and actual surgical discomfort, whereas 
others may be more susceptible to lack of coping and catastrophizing (‘football player 
patients’) needing a lot more attention. Holistic patient management is all important in 
pain management, with alternative techniques (hypnosis and acupuncture). 
The patients’ expectations are paramount and it is known that all patients expect pain 
when visiting their dentist.5 It is important for clinicians to point out to patients that 
they are not magicians but surgeons and it is impossible to do complex surgery on 
patients without causing some minor discomfort intra-operatively and, occasionally, 
moderate pain post-operatively. Perioperative dental pain is not managed well in 
dentistry and is the most common adverse event reported by dentists6,7 and by 
patients.8 Regarding the dental experience involving pain, 60% of a representative 
sample of the general population aged 15 years or more has reported pain at least once 
during a dental visit.9 
Local anaesthetic injection plus analgesic tablets are NOT enough! Local anaesthesia is 
only a small part of operative pain management.2 Pain and its management is complex as 
the individual’s pain experience is unique and based upon his/her gender, beliefs, 
religion, ethnicity, prior pain experience, psychological factors, nocebo and placebo 
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effects etc.5 There are many psychological factors driving the response to acute pain 
related to surgery and in relation to the development of chronic post-surgical pain. 
The key aspects for operative pain management include: 
o Patient factors including: 
• Managing the patients’ expectations and anxiety. Education 
about pre- and post-operative events with clear and frank 
two-stage consent allowing patients some control of their 
treatment decisions; 
• Appropriate anxiolysis (assessment and management) will 
elevate pain thresholds and improve pain management. 
o Medical aspects including: 
• Optimal Local anaesthetic practise; 
• Appropriately prescribed analgesics. 
o Surgical factors: It is also acknowledged that good surgical practice minimizes 
pain for the patient, including minimal access technique. 
o Post-op advice with accessibility for patient contacting the practice and/or 
surgeon with clear post-operative advice on mouthcare maintenance and 
analgesics use. 
<ch1/1>How do we minimize systemic complications of dental LA? 
Over one billion dental local anaesthetic injections are given annually worldwide (pers 
communication: Malamed S, FDI lecture 2017). The reported adverse reaction rate is 
1:1,000,000 and the mortality (death) rate from dental local anaesthetic injections has 
been stated at 0.000002%. Allergies are very rare and can often be psychosomatic.10 
The definition of the term ‘adverse reaction’ covers noxious and unintended effects 
resulting not only from the authorized use of a medicinal product at normal doses, but 
also from medication errors and uses outside the terms of the marketing authorization, 
including the misuse and abuse of the medicinal product. The range of pharmaceuticals 
used in dental practice is relatively small, consisting primarily of sedatives, local 
anaesthetics, analgesics and antibiotics. Adverse drug reactions are categorized as 
type A or type B. 
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• Type A reactions are more common and and are generally attributable to known 
pharmacological or toxic effects of the drug. 
• Type B reactions are idiosyncratic, unpredictable, acute/sub-acute, not related 
to a known mechanism 
The most common adverse reactions to LA include: 
• Vasovagal attack or faint: nearly all patient-related collapses during dental LA 
are faints. A study carried out at Dundee Dental School showed that of 27 cases of 
‘local anaesthetic allergies’ only one was caused by the anaesthetic injection (and this 
was a sulphite allergy, not a drug allergy).11 This can be overcome by good chairside 
manner and observation of the patient. If a prolonged procedure is anticipated, the 
patient should have eaten prior to the procedure or be provided with a glucose drink. 
Any patient who is anxious must be provided with suitable anxiolysis. 
• Allergy to local anaethetic agents is very rare and usually related to adjunctive 
agents including bung (Latex),12 the preservative (sodium metabisulphites), antiseptic, 
vasoconstrictor or, very rarely, the local anaesthetic agent. Most LA agents are now 
latex free. Esters are highly allergenic and there are no documented allergy to amides. 
The patient is more likely to be allergic to bisulphate preservative (needed for vaso-
constricture). The least allergenic LAs are Mepivicaine or plain Prilocaine. Allergy is not 
dose dependent unlike toxicity.13 The signs of allergy include breathlessness, 
disorientation and distress, urticaria hypotension and collapse. Immediate action is 
required including; Call for help, 1:1000 Units Epinephrine IM and provision of Oxygen. 
• Adverse effects (Table 1) usually caused by high plasma concentration of LA 
drug resulting from: 
-Inadvertent intravascular injection related to block injections; 
-Excessive dose or rate of injection; 
-Medically compromised patients: 
• Delayed drug clearance; 
• Drug interactions. 
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Adverse events happen in relation to the concentration and dose of LA. Size and health 
of your patient and essentially intravascular injections which are more likely with block, 
intraosseous and periodontal injections. Minimizing risk of overdose includes avoiding: 
– All 4 quadrant treatment (staged treatment for elderly patients); 
– Plain LA (no vasoconstrictor); 
– Full cartridge injections (should commonwealth move to 1.7 ml 
cartridges?); 
– Exceeding maximum recommended dose (Table 2) 
Young and elderly patients must be suitably assessed for their weight. A child of 5 
years weighs 18−20kg − maximum dose 88 mg (2 x 2.2 ml lidocaine cartridges). Due to 
their size children are at high risk of toxicity. Goodson and Moore have documented 
catastrophic consequences of this drug interaction in paediatric patients receiving 
procedural sedation, along with excessive dosages of local anesthetics.14 
Medical issues: Any health aspects that include metabolizing or excreting. The main 
medical risks are: 
– Patients with cardiovascular diseases; 
– Patients with endocrine diseases; 
– Patients with CNS disorders; 
– Patients with lung diseases. 
Aspiration during dental LA is a legal requirement in the UK. Avoiding intravascular LA 
is possible by avoiding injection intra-vascularly by using aspiration and avoiding 
intraosseous injections and being aware of the increased vascularity of inflamed tissue 
whilst always observing clinical reactions by: 
• Talking to patients during the injection and monitoring their ECG/blood pressure 
to realize early symptoms of central-nervous and cardiovascular toxicity if they are at 
risk; 
• Stop injection immediately when early symptoms are realized; 
• Consider the time course for development of toxic signs (5−10 min) 
• Avoiding long-acting and potent substances (Bupivacaine is the most neurotoxic 
agent). 
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A recent survey of 2731 patients undergoing LA for dental treatment reported that 
45.6% patients had medical risk factors (mostly cardiovascular). The overall LA 
complication rate was 4.5% complications (5.7% in risk patients/ 3.5% non-risk 
patients), which were most commonly dizziness, tachycardia, agitation and 
bronchospasm. Severe complications including seizures and bronchospasm occurred 
rarely (0.07%). Overall, there were less complications with articaine 4% I:100K 
epinephrine compared with articaine 4% I:200K epinephrine.16 articaine is less toxic 
than lidocaine at the same concentration as it has high binding plasma rate reducing 
crossing the placenta or blood brain barrier. Metabolism of articaine occurs in tissue 
and plasma (rather than in the over??? for lidocaine or bupivacaine) and lidocaine only 
50% is degraded after 1.5−3 hours which is much slower than articaine of which 50% is 
eliminated after 20 minutes (Table 3). 
All suspected adverse events to local anaesthesia should be reported and this can be 
done online via the MHRA Yellow Card website (at www.mhra.gov.uk/yellowcard) or by 
calling the National Yellow Card Information Service on 0808 100 3352 (10am to 2pm 
Monday−Friday). In addition, dental practices should sign up to receive MHRA alerts. 
Subscribe using the following link: https://www.gov.uk/drug-device-alerts/email-
signup 
<ch1/1>What are the medical modifiers for dental LA? 
There are very few absolute medical contra-indications to local anaesthetic and these 
are listed in Table 4. There are some relative but not absolute contra-indications for 
adrenaline use including: 
• Hypertension, angina pectoris, heart failure; 
• Diabetes mellitus; 
• Bronchial asthma; 
• Regularly taken medication (TCAs, MAO inhibitors, beta-blockers); 
• Pregnancy; 
• Narrow-angle glaucoma. 
However, prudent avoidance of blocks, or aspirating when using blocks and slow 
injection, low dosage and staged treatments allows the use of adrenaline in patients 
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with these conditions. Use of low dose adrenaline LA agents may be used in these cases 
(Table 5).16 
o Specific systemic complications have been reported with dental local 
anaesthetics including methaemoglobinemia. Benzocaine should no longer be used. 
Prilocaine should not be used in children younger than 6 months old, in pregnant women, 
or in patients taking other oxidizing drugs. The dose should be limited to 2.5 mg/kg. At 
low levels (1−3%), methaemoglobinemia can be asymptomatic, but higher levels (10−40%) 
may be accompanied by any of the following complaints: cyanosis, breathlessness, 
tachycardia, fatigue and weakness.17 
o Drug interactions 
-Lidocaine can interact with CNS depressants and with H2 Blocker (PPIs) 
-Epinephrine 
-Propranolol is the only non-selective beta-blocker reported to 
have the potential to cause severe hypertension and reflex 
bradycardia in the presence of epinephrine.  
-A significant risk does not appear to be associated with the use 
of epinephrine and cardio selective beta-blockers. 
Many complications or adverse events arise during dental local anaesthetics due to the 
patient being overly anxious or not well informed. Thus, the LA technique used must 
address several aspects including: 
▪ Care to recheck medical history at every visit 
-Check patient’s recent prescription chart (<2 weeks); 
-Check patient’s blood pressure; 
-Care with small patients: 
-Children; 
-The elderly (sacropenia is the loss of muscle mass which reduces 
body mass significantly after 60 years). 
▪ Good pre-operative assessment of medical history and anxiety levels; 
▪ Reassurance/warnings (avoid showing patient the syringe); 
▪ Give the patient feelings of control; 
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▪ Distraction; 
▪ Topical LA; 
▪ Place fingertip near region where the needle is about to inject; 
▪ Warm LA cartridges; 
▪ Slow injections are less painful and more effective.10 
A key factor in patient satisfaction is a sense that the care-giver is doing his/herr 
best and is genuinely concerned that therapy is adequate.18 
<ch1/1>How do we minimise regional complications of LA? 
Avoiding failed LA 
There are many myths regarding failed LA in dentistry.19 Local anaesthesia failure is 
often assumed to be the fault of the clinician due to the general overestimation of the 
effectivity of block anaesthesia providing pulpal anaesthesia in the mandible. The onset 
of lip numbness occurs usually within 5-9 minutes of injection and pulpal anaesthesia 
follows later 15-16 minutes.20-22 Slow onset of pulpal anesthesia (after 15 minutes) 
occurs approximately 19-27% of the time in mandibular teeth and approximately 8% of 
patients have onset after 30 minutes.23 Lip numbness does not guarantee pulpal 
anaesthesia and failure to achieve lip numbness occurs about 5% of the time with 
experienced clinicians.24,25  
Inferior dental blocks are remarkably inefficient at providing pulpal anaesthesia for 
dental procedures.26-28 Malamed stated the rate of inadequate anaesthesia ranged from 
31% to 81%. When expressed as success rates, this indicates a range of 19% to 69%. 
These numbers are so wide ranging as to make selection of a standard for rate of 
success for IANB seemingly impossible.10 There are many other possible components 
contributing to LA failure including; 
• Anatomical variation Flared or broad mandibular rami may require modified IDB 
technique.29  
• Patients who have a poor history to responding to LA.30  
• Speed of IDB injection - A slow inferior alveolar nerve block injection (60 
seconds) results in a higher success rate of pulpal anaesthesia and less pain than a 
rapid injection (15 seconds).31  
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• Pathological (infection)32,33 Pulpitis  is a challenging clinical problem, and can only 
be overcome by increasing the dose of anaesthetic in the area, with increased accuracy 
of the placement of the anaesthetic solution.34  
• Choice of technique, insufficient dose, poor technique, damaged LA due to poor 
storage.35  
How do we manage failed IDB?  
o Giving another inferior alveolar nerve block does not help the patient if they 
feel pain during operative procedures. The second injection does not provide additional 
anesthesia—the first injection is just “catching up”.36  
o Increasing the volume to two cartridges of lidocaine or increasing the 
epinephrine concentration from 1:100,000 to 1:50,000 (20, 21) will not provide better 
pulpal anesthesia.37,38  
o Use higher concentration agents for block injections is not evidenced to improve 
efficacy.39-41  
o Specifically articaine compared with lidocaine IDBs has no or limited additional 
efficacy.42,43 
o Computed techniques do not ad advantage for IDB efficacy.44  
o There is increasing evidence that additional injections (buccal infiltration, 
intraseptal, intraligamental, intra osseous) can enhance and even replace IDBS. 
Supplemental injections can improve mandibular pupal anaesthesia.33 
o Recent studies report that giving a buccal infiltration of a cartridge of 4% 
articaine with 1:100,000 epinephrine after an inferior alveolar nerve block significantly 
increased success (88%) when compared to a lidocaine formulation (71% success).45,46 
In a study of 182 patients 122 achieved successful pulpal anesthesia within 10 minutes 
after initial IANB injection only 82 experienced pain-free treatment. Additional 
articaine buccal infiltration (ABI) and Intraosseous (IO) allowed more successful (pain-
free) treatment.47  
• IANB + ABI 84% pain free RX 
• IANB + IO  68% pain free Rx 
• IANB + PDL  48% pain free Rx 
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• IANB alone  32% pain free Rx 
o The addition of intraligamental injections may assist in extractions.48,49 
However, intraligamental injections are unlikely to be as effective at IDB alone for 
other dental procedures. 
o The addition of the intraosseous injection after an inferior alveolar nerve block, 
in the first molar, will provide a quick onset and a high incidence of pulpal anesthesia 
(approximately 90%) for 60 minutes. Clinically, the supplemental intraosseous injection 
works very well but systemic cardiac effects are related to the ‘intravenous’ nature of 
this injection.51-53  
There is no evidence supporting using direct or indirect Halstead IDB technique or the 
improved efficacy of using Gow Gates of Akinosi techniques. The main issues appear to 
be the overestimation of the efficacy of IDBs in general, impatience and lack of 
awareness that one must wait over 15 minutes for maximum efficacy of a lidocaine 
block, in addition the lack of use of alternative techniques that provide improved pulpal 
anaesthetic rates for anterior teeth. 
<ch1/1>How do we minimise regional complications of LA? 
Most of these complications can be avoided by careful technique and avoidance of 
intravascular injections but even when clinicians use the utmost care, by aspirating 
before the injection and noting anatomical landmarks, intra-arterial injections can 
occur during inferior alveolar nerve blocks.54 Fortunately, permanent damage to nerves, 
facial and oral tissues, and eyes is rare. Possible regional complication related to IDBs 
include; 
• Facial palsy likely due to poor IDB technique with too deep or superior injection 
through the coronoid process into the sheaths of the parotid gland through which the 
facial nerve travels.55  
• Tissue trauma-haematoma trismus. In patients who have coagulopathies or 
platelet malfunction avoidance of block injections is advisable but occasionally un 
avoidable. 
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• Fracture of the needle is more likely to occur with 30 gauge needles, using 
needles too short leaving no additional space between the Hub and tissues and pre 
bending of the needle prior to injection.56,57  
• Ophthalmic complications.58  
• Nerve injury Nerve injury related to IDB injections may cause permanent 
neuropathy in lingual and inferior alveolar nerves often associated with combined 
numbness, paraesthesia and neuropathic pain. Though LA related permanent nerve 
injury is rare (approximately 1in 52-7K IDBs) once the injury occurs approximately 75% 
may resolve but the remaining 25% are untreatable. Most patients with trigeminal 
nerve injuries experience chronic pain in their lip teeth and gums or tongue and gums 
depending on which nerve is damaged. This is a lifelong burden that these patients find 
difficult to accommodate to especially when they were never warned about the possible 
risk. The risk of nerve injury can be mitigated by altering the block technique or by 
avoiding block anaesthesia altogether. The risk factors for nerve injury related to 
dental anaesthesia are listed in Table 6 
The incidence of persistent neuropathy related to dental IDBs is rare, estimated to be 
between 1 in 14K temporary and 1 in 52K permanent (25% permanent),59 1:26,762 and 
1:160,571,63  1 in 27.415 cases,74 1 in 785,000 injections, to 1 in 13,800.970.66 The 
majority of nerve injuries are painful in patients seeking care, consistent with other 
surgical sensory neuropathies leading to a condition known as chronic post-surgical pain. 
Unfortunately for these patients the unforeseen complication of routine dental care 
leads to life changing orofacial pain with subsequent significant functional and 
psychological sequelae. 
Management   There is no evidenced based treatment for these nerve injuries we have 
to sit and wait whilst caring for the patients. If pain is caused during n IDB arrange to 
contact the patient the next day to exclude persistent neuropathy (pain, numbness and 
or altered sensation), reassure them that 75% recover, medical intervention including 
NSAIDs, Vitamin B and steroids as used for spinal iatrogenic nerve injuries may be 
effective in reducing neural inflammation and irritation but there is no evidence to 
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support this aside form patients being reassured that their clinician is trying to help 
them.  
Should patients be warned of possible rare nerve injuries related to dental LA? Based 
upon the Montgomery ruling clinicians must now ensure that patients are aware of any 
“material risks” involved in a proposed treatment, and of reasonable alternatives, 
following the judgment in the case Montgomery v Lanarkshire Health Board. This is a 
marked change to the previous “Bolam test”, which asks whether a doctor’s conduct 
would be supported by a responsible body of medical opinion. This test will no longer 
apply to the issue of consent, although it will continue to be used more widely in cases 
involving other alleged acts of negligence. Thus one has to question when would a 
permanent burning tongue or elcited neuralgic pain of the face caused whenever to eat, 
kiss, speak or go out in the cold is not material to a patient? Suggested routine consent 
was suggested in the US in 1939.72  In Germany there is already a legal precedent to 
warn all patients undergoing dental La of possible nerve injury and any patient 
undergoing spinal or epudural injections in the UK must warn patients of possible 
permanent motor or sensory nerve injuries in 1 in 57K.73  
Thus, prevention of LA nerve injuries is paramount most effectively achieved by 
avoiding block anaesthesia. Dentistry is the ONLY healthcare profession taught to aim 
for nerves blindly during block injections! There is increasing pressure to use 
ultrasound neural location to minimise systemic toxicity and nerve injuries as practiced 
in regional block anaesthesia elsewhere in the body. Other strategies would include 
avoiding risk factors (Table 6 51-79) but mainly avoid block anaesthesia and using 
infiltration techniques instead. 
<ch1/1>What is wrong with our current practice and how can we do better? 
Proposed Tailored smart LA practice 
o What technique? 
o What Agent? 
o What LA volume? 
The limitations of IDB in providing swift mandibular pulpal anaesthesia is recognised 
and recent evidence supports the use of infiltration mandibular dentistry. 
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Interestingly, for decades dentists have routinely undertaken maxillary dentistry with 
infiltrations accepting that nerves within bone are accessible to submucosal local 
anaesthetic techniques. With respect to maxillary infiltration anesthesia, some studies 
have found 4% articaine to be more effective than 2% lidocaine for lateral incisors but 
not molars,74 while others reported no clinical superiority for this injection.75,76  A 
recent randomized controlled trial found a statistically significant difference 
supporting use of 4% articaine in place of 2% lidocaine for buccal infiltration in 
patients experiencing irreversible pulpitis in  maxillary posterior teeth.77  
As mentioned previously nerve blocks are related to nerve injury and there are no 
indications to use palatal, incisal or infraorbital nerve blocks for dentistry except in 
very rare exceptions; for example spreading infection from canines or premolar use of 
block anaesthesia will prevent the need for GA drainage and extractions. Several 
studies report the lack of indications for palatal block injections. 78,79 There is 
increasing evidence that additional injections (buccal infiltration, intraseptal, 
intraligamental, intra osseous) can enhance and even replace IDBS.32,35,47,77 Lidocaine 
infiltration is likely as effective as articaine for maxillary dentistry.80 A recent 
systematic review highlighted that there is no benefit in using articaine infiltration for 
maxillary dentistry but articaine os 3.6 more times effective than lidaocaine for 
mandibular infiltration dentistry.81   
<ch1/1>Can articaine 4% infiltration replace lidocaine 2% IANBs for routine 
dentistry? 
Undoubtedly using infiltration and not IDBs improves patient comfort as patients will 
undoubtedly prefer having full lingual sensation and shorter duration LA anaesthesia 
after dental treatment.32 Not only are buccal infiltration techniques proving as or more 
effective that IDBs but intraligamental injections can also be used effectively for 
exodontia as intraligamental injections are effectively intravascular with more likely 
systemic effects but in addition there is reported higher post restorative pain 
levels.82-83 
<ch1/1>IDBs are unnecessary to treat  
o pulpitic mandibular molars in adults, 84-85 
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o for exodontia in adults and children, 86-87 
o IDBs are unnecessary to treat for implant surgery. 88One hundred and twenty 
patients requiring the placement of a single implant in order to replace a missing first 
mandibular were randomly allocated to two groups comparing crestal with infiltration. 
No nerve damage occurred using either anaesthesia types, therefore the choice of type 
of anaesthesia is a subjective clinical decision. However, it may be preferable to use a 
low dose (0.9 ml) of subperiosteal anaesthesia, since it is unnecessary to deliver 7.2 ml 
of articaine to anaesthetise a single mandibular molar implant site.89  
o IDBS are unnecessary for restorative mandibular care in kids.90 However in a 
recent study of 57 paediatric patients undergoing restorative mandibular treatment 
reported a higher success and less painful treatment with IANB. There was no 
statistically significant difference in local analgesia success between articaine and 
lignocaine when delivered via buccal infiltration.91  
<ch1/1>Benefit of computerised systems for infiltration techniques 
There is limited evidence to support that computerised infiltration systems are more 
effective but those regularly using these systems empirically report better patient 
acceptance and comfort during injections.92  
<ch1/1>What is the best agent? 
Articaine (4-methyl-3-[2-(propylamino)-propionamido]-2-thiophene-carboxylic acid, 
methyl ester hydrochloride) is a unique amide LA in that it contains a thiophene, 
instead of a benzene, ring. The thiophene ring allows greater lipid solubility and potency 
as a greater portion of an administered dose can enter neurons. It is the only amide 
anaesthetic containing an ester group, allowing hydrolysation in unspecific blood 
esterases. About 90% of articaine metabolises quickly via hydrolysis in the blood into 
its inactive metabolite articainic acid, which is excreted by the kidney in the form 
articainic acid glucuronide. Its metabolism is age dependent, where clearance and 
volume of distribution decreases with increasing age. The elimination serum half-life of 
articaine is 20 minutes and of articainic acid is 64 minutes.93-95 articaine at different 
three comparative lidocaine concentrations provide more effective in providing 
mandibular pulpal anaesthesia,96 however, articaine is 3.6 times more effective for 
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mandibular infiltration dentistry97 and a recent study demonstrated that 2% articaine 
is as effective as 4% articaine using IDB for mandibular dental extraction in adults.98,99 
In summary more research is needed before recommending replacing 4 with 2% 
articaine for all dental procedures 
Concentration of epinephrine may be reduced from 1in 100 to 1in 200 and equally 
effective for third molar extraction 100 and epinephrine concentration of 1 in 400 may 
only be required for paediatric extractions using 4% articaine.101   
So is the future agent for dental anaesthesia 2% articaine with 1: 200 -400K 
epinephrine for all LA techniques and dental procedures in Adults? Could we use 
Epinephrine Free LA for paedodontic dentistry? Further research is needed 
<ch1/1>What LA volumes should we be using? 
The most common LA cartridge volume used worldwide is 1.8ml,102 Dentists in France 
and Japan use only 1ml cartridges and the commonwealth 2.2ml cartridges.Dictation of 
LA volume should be diameter of nerve and accuracy of technique in 40 procedures in 
32 patients Buccal Infiltration Average LA volume 0.59ml with 97.5% effective pain 
control.103  
Infiltration techniques require significant less LA Volume compared with block 
techniques (0.6-9ml), Gow Gates only block anaesthesia technique where full cartridge 
1.8 -2.2ml is recommended and infraorbital LA bloc requires 1.8-2.2 ml.104  
Figure 4 Volume recommendation for maxillary  local anaesthesia in dentistry taken 
from Malamed SF Techniques of maxillary anaesthesia in Handbook of local anaesthesia 
Malamed SF 6th edition Mosby Elsevier 2013, St Louis Page 223. 104 
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Figure 5 Volume recommendation for mandibular local anaesthesia in dentistry taken 
from Malamed SF Techniques of maxillary anaesthesia in Handbook of local anaesthesia 
Malamed SF 6th edition Mosby Elsevier 2013, St Louis Page 223.104 
 
Thus the continued use of 2.2ml cartridges should be questioned and changed to 1.8ml 
cartridges which would improve patient safety and likely impact minimally on repeated 
injections 
The future interest is the possibility of development of newer improved agents 
(sensory blocking agents only) and devices and techniques for achieving profound 
sensory anesthesia. A nasal spray (http://clinicaltrials.gov/ct2/show/NCT01302483 ) 
has shown to anesthetize maxillary anterior six teeth is set to be tested in an FDA 
Phase 3 trial, which will assess the spray's effectiveness compared to the current “gold 
standard” treatment - painful anesthesia injections. Buffering of acidic local 
anaesthetics to more neutral physiological pH allows for speedier LA onset and is 
already in use in the US.Another development is a syringe micro vibrator (SMV),105 a 
new device being introduced in dentistry to alleviate pain and anxiety of intraoral 
injections. 
<ch1/1>Summary 
A radical change in practice is required with regard so many aspects of patient safety 
based upon current evidence whilst acknowledging further research would be ideal. 
With the current research legislation, undertaking simple efficacy studies of existing 
commonly used LA agents is prohibitively expensive and unlikely to be funded by 
pharmaceutical companies, limiting the provision of future robust supportive research. 
Infiltration LA for implantology is a good example where common sense and application 
of optimal technique has occurred without robust evidence base providing safer more 
effective patient care. 
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o A tailored approach to dental local anaesthesia should be recommended to 
prevent the continued unnecessary use of IDBs when infiltration anaesthesia is likely 
more effective for most dental procedures. Tailored LA is dictated by the site and 
procedure See Figure 3 summarising the optimal anaesthetic techniques  
o The lack of safety giving blind block injections with likely systemic and local 
complications (especially nerve injury) may be considered ‘indefensible’. 
o IDBs should be prescribed in limited cases when indicated (see Tailored LA 
below) 
o Consent for LA, in the light of Montgomery consent recommendations, all 
patents should be routinely warned of a risk of nerve injury when routinely undergoing 
Dental local anaesthesia as they are already in Germany and in the UK related to 
epidural or spinal injections  
o Reduction of epinephrine levels is likely possible for most dental procedures also 
improving patient safety and minimising systemic effects and reducing problems in 
medically compromised patients 
o Revisitation of the required cartridge volume is necessary and recommendation 
for the use of 1.8ml versus 2.2ml cartridges will improve patient safety 
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Table 1 Adverse effects are usually caused by high plasma concentration of either 
LA drug or adjunctive content resulting from; 
Vasoactive adjunctive agents are added to 
• Delayed absorption of LA 
• Reduction of the systemic plasma levels of the LA 
• Prolongation of the duration of action of the LA 
• Reinforcement of the intensity of the LA’s effects  
– Not dependent on concentration 
• Reduction of local blood perfusion 
 
 
Table 2  Maximum doses of local anaesthetic agents 
Drug Max dose 1/10th cartridge 
2% lidocaine 4.4mg/kg 3.6 - 4.4mg 
2% mepivacaine 4.4mg/kg 4.0mg 
3% mepivacaine 4.4mg/kg 6.0 mg 
3% prilocaine 6.0mg/kg 6.6mg 
4% prilocaine 6.0mg/kg 8.0mg 
4% articaine 7.0mg/kg 6.8 - 8.0mg 
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Table 3 Lidocaine toxicity 
At serum levels patients may complain of; 
• 1-5 mcg/mL 
– Tinnitus 
– Lightheadedness 
– circumoral numbness 
– Diplopia 
– metallic taste  
– may complain of nausea and/or vomiting, or they may become more 
talkative.  
• 5-8 mcg/mL 
– nystagmus, slurred speech, localized muscle twitching, or fine 
tremors may be noticed. Patients also have been noted to have hallucinations at 
these levels.  
•  8-12 mcg/mL 
– focal seizure activity occurs; this can progress to generalized tonic-
clonic seizures. Respiratory depression occurs at extremely high blood levels (20-
25 mcg/mL) and can progress to coma. 
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Table 4 Absolute medical contraindications for LA include;  
• Pheochromocytoma   adrenaline producing tumour of the adrenal 
gland 
• Hyperthyroidism  Elevated levels of thyroxine which lead to  
                                                          sensitisation of 
adrenaline receptors 
• Tachycardic arrhythmias Unstable ventricular fibrillation 
• Sulphite allergy    Anaphylactic reaction 
 
 
Table 5 Low dose adrenaline LA agents may can be used in these cases  
Articaine 4% with adrenaline 1: 400,000 12.5 ml * 
Articaine 4% with adrenaline 1: 200,000 8 ml * 
Articaine 4% with adrenaline 1: 100,000 4 ml * 
Articaine 4% without adrenaline 7 ml * 
Mepivacaine 3% without adrenaline 10 ml * 
Mepivacaine 2% without adrenaline 15 ml * 
 
Table 6 32, 59-79 Risk factors for nerve injury related to dental local anaesthesia 
Block anaesthesia 59 
 
Lingual nerve > IAN  60  
Blind block injections 
There is criticism of teaching 
the use of blind injections in 
dentistry 
 
61-63 
 
 
32 
 
• Technique or 
Anatomy? 
No evidence that direct Halstead causes more 
lingual nerve injuries than indirect technique 
Concentration of LA agent 59, 60, 64-71 
Speed of injection  
Multiple injections 59 
Severe pain on injection 60% more likely to experience persistent 
neuropathy 59 
LA Agent toxicity Increasing toxicity at same concentration 
Bupivicaine> Mepivacaine> 
Prilocaine>Lidocaine>Articaine 
• Type of 
vasoconstrictor? 
• Sedated GA 
• Lack LA 
aspiration 
No evidence 
No evidence 
No evidence 
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Figure 3 Summarising Mandibular LA infiltration techniques 
 
 
 
 
 
